Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population (vol 189, pg 689, 2021)

Michelino De Laurentiis; Simona Borstnar; Mario Campone; Ellen Warner; Javier Salvador Bofill; William Jacot; Susan Dent; Miguel Martin; Alistair Ring; Paul Cottu; Janice Lu; Eva Ciruelos; Hamdy A. Azim; Sanjoy Chatterjee; Katie Zhou; Jiwen Wu; Lakshmi Menon-Singh; Claudio Zamagni

doi:10.1007/s10549-021-06374-6

Retour

Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population (vol 189, pg 689, 2021)

Article de revue

Avec comité de lecture

Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population (vol 189, pg 689, 2021)

Michelino De Laurentiis, Simona Borstnar, Mario Campone, Ellen Warner, Javier Salvador Bofill, William Jacot, Susan Dent, Miguel Martin, Alistair Ring, Paul Cottu, …

Breast cancer research and treatment, Vol.191(1), pp.223-224

01/01/2022

DOI: https://doi.org/10.1007/s10549-021-06374-6

PMID: 34625861

Résumé

Life Sciences & Biomedicine

Oncology

Science & Technology

Indicateurs

1 Consultations de la notice

See more details

Détails

Titre: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population (vol 189, pg 689, 2021)
Créateurs - sans rôle: Michelino De Laurentiis - Ist Nazl Tumori IRCCS Fdn Pascale, Dept Breast & Thorac Oncol Director, Div Breast Med Oncol, Naples, Italy
Simona Borstnar - Inst Oncol Ljubljana, Ljubljana, Slovenia
Mario Campone - Université de Nantes
Ellen Warner - Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
Javier Salvador Bofill - Virgen Rocio Univ Hosp, Biomed Inst, Seville, Spain
William Jacot - Montpellier Canc Inst, Montpellier, France
Susan Dent - Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada
Miguel Martin - Univ Complutense, CIBERONC, GEICAM, Gregorio Maranon Gen Univ Hosp, Madrid, Spain
Alistair Ring - Royal Marsden Hosp NHS Fdn Trust, Sutton, Surrey, England
Paul Cottu - Curie Inst, Paris, France
Janice Lu - USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
Eva Ciruelos - Univ Hosp 12 Octubre, Clara Campal Comprehens Canc Ctr, HM CIOCC, Madrid, Spain
Hamdy A. Azim - Cairo Univ, Fac Med, Cairo, Egypt
Sanjoy Chatterjee - Tata Med Ctr, Kolkata, India
Katie Zhou - Novartis Pharmaceut, E Hanover, NJ USA
Jiwen Wu - Novartis Pharmaceut, E Hanover, NJ USA
Lakshmi Menon-Singh - Novartis Pharmaceut, E Hanover, NJ USA
Claudio Zamagni - Azienda Ospedaliero Univ Bologna, Bologna, Italy
Détails de publication: Breast cancer research and treatment, Vol.191(1), pp.223-224
Éditeur: Springer Nature
Nombre de pages: 2
Identifiants: 99140063609311
Unité académique: Institut de Recherche en Cancérologie de Montpellier - IRCM
Langue: English
Type de ressource: Journal article